Twist Bioscience Corporat... (TWST)
NASDAQ: TWST
· Real-Time Price · USD
32.91
2.09 (6.78%)
At close: May 12, 2025, 3:59 PM
33.40
1.49%
After-hours: May 12, 2025, 06:17 PM EDT
Twist Bioscience Revenue Breakdown
| Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 |
|---|---|---|---|---|---|---|
| Antibody Discovery Revenue | 20.33M | 23.17M | 24.17M | 12.66M | 4.54M | 4.59M |
| Antibody Discovery Revenue Growth | -12.27% | -4.13% | +90.88% | +178.61% | -1.07% | n/a |
| Dna And Biopharma Libraries Revenue | 13.93M | 10.2M | 6.15M | 72.67M | 35.19M | 26.71M |
| Dna And Biopharma Libraries Revenue Growth | +36.58% | +65.90% | -91.54% | +106.49% | +31.75% | n/a |
| Ngs Tools Revenue | 169.13M | 123.71M | 99.31M | 8.04M | n/a | n/a |
| Ngs Tools Revenue Growth | +36.72% | +24.56% | +1135.38% | n/a | n/a | n/a |
| Oligo Pools Revenue | 16.91M | 14.49M | 12.42M | 38.96M | n/a | n/a |
| Oligo Pools Revenue Growth | +16.68% | +16.62% | -68.11% | n/a | n/a | n/a |
| Synthetic Genes Revenue | 92.68M | 73.54M | 61.51M | n/a | n/a | n/a |
| Synthetic Genes Revenue Growth | +26.02% | +19.56% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 63.67M | 56.18M | 53.14M | 56.79M | 55.62M | 52.84M | 47.39M | 46.06M | 53.97M | 42.32M | 54.16M | 53.69M | 54M | 51.1M | 38.24M | 34.48M | 34.39M | 28.79M | 27.18M | 22.49M | 27.19M | 26.41M | 24.42M | 21.32M | 19.12M | 15.26M | 12.95M | 11.26M | 9.98M | 9.26M | 8.41M | 5.92M |
| Selling, General, and Administrative Revenue Growth | +13.34% | +5.71% | -6.43% | +2.11% | +5.26% | +11.50% | +2.90% | -14.65% | +27.50% | -21.85% | +0.87% | -0.56% | +5.68% | +33.61% | +10.92% | +0.26% | +19.44% | +5.91% | +20.89% | -17.30% | +2.97% | +8.12% | +14.55% | +11.48% | +25.33% | +17.80% | +15.08% | +12.81% | +7.72% | +10.16% | +42.07% | n/a |
| Research and Development Revenue | 23.92M | 21.31M | 21.13M | 22.47M | 24.15M | 23.1M | 23.75M | 24.53M | 27.38M | 31.24M | 29.61M | 36.84M | 31.23M | 22.63M | 19.44M | 19.84M | 15.79M | 14M | 11.64M | 10.44M | 10.63M | 10.3M | 10.5M | 9.01M | 8.91M | 7.27M | 6.07M | 5.27M | 4.71M | 4.3M | 4.85M | 5.28M |
| Research and Development Revenue Growth | +12.25% | +0.82% | -5.94% | -6.96% | +4.55% | -2.72% | -3.19% | -10.41% | -12.36% | +5.53% | -19.64% | +17.96% | +38.01% | +16.39% | -1.99% | +25.63% | +12.79% | +20.32% | +11.41% | -1.74% | +3.22% | -1.90% | +16.53% | +1.12% | +22.47% | +19.92% | +15.13% | +11.82% | +9.48% | -11.30% | -8.07% | n/a |